Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | DPP4 | P27487 | 7/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MARS1 | P56192 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27282913 | 0.88 | CNR1 (0.35) | JAK2CNR1NPC1ALPLMARS1 | |
| SCHEMBL27082828 | 0.84 | ROCK2 (0.39) | JAK2CNR1NPC1CHRNA7MARS1 | |
| SCHEMBL27282921 | 0.84 | NPC1 (0.35) | JAK2NPC1 | |
| SCHEMBL27282887 | 0.83 | KDM4E (0.37) | CNR1POLBMAPT | |
| SCHEMBL27282909 | 0.80 | JAK2 (0.44) | JAK2CNR1JAK1TYK2 | |
| SCHEMBL27282908 | 0.80 | JAK2 (0.42) | JAK2CNR1NPC1DPP4DPP8 | |
| SCHEMBL27282911 | 0.80 | JAK2 (0.37) | JAK2CNR1NPC1ALPLJAK1 | |
| SCHEMBL27282741 | 0.74 | NUDT1 (0.39) | JAK2NPC1JAK1TYK2 | |
| SCHEMBL27282729 | 0.73 | JAK2 (0.44) | JAK2JAK1TYK2 | |
| SCHEMBL14661779 | 0.72 | JAK2 (0.73) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-07-04 | — | — | US | disclosed |
| EP-4313971-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2024-02-07 | — | — | EP | disclosed |
| CN-117157289-A | Substituted pyrrolecarboxamides, process for their preparation and their use as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2022207404-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217969-A1 | SUBSTITUTED PYRROLE CARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | CDC7, CDK7, CDK17 | JAK2 658/4885CNR1 2599/4885NPC1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.